Heart risks of glucose-lowering drugs being overlooked in clinical trials

March 12, 2014

Why is heart failure not more rigorously assessed in clinical trials of antidiabetes drugs? In a Personal View, published in The Lancet Diabetes & Endocrinology journal, Professor John McMurray of The University of Glasgow and colleagues review evidence that hospitalization for heart failure is one of the most common and prognostically important complications of diabetes. Moreover, increasing evidence shows that some glucose-lowering drugs increase the risk of heart failure. Yet, heart failure is rarely considered as a key outcome, or even part of composite cardiovascular outcomes, in clinical trials of glucose-lowering drugs.

Previously, the ability of an antidiabetes to lower glucose was used in clinical trials accepted as a surrogate of its ability to reduce the risk of microvascular disease, and possibly cardiovascular risk. Recent evidence has suggested, however, that some antidiabetes drugs may increase patients' cardiovascular risk, despite their ability to effectively lower blood glucose. These findings have prompted the FDA and EMA to make new regulations requiring trials for new antidiabetes drugs.

Such cardiovascular outcomes trials have typically used so-called major adverse cardiovascular events (MACE) as a primary outcome. This combined outcome usually includes cardiovascular death, heart attack, and stroke. However, as McMurray and colleagues explain, can be more common than any of these other cardiovascular outcomes, especially in patients with advanced diabetes, and it is also more closely associated with premature death. Thus, its omission as a key endpoint in clinical trials could mean that important cardiovascular effects of the glucose-lowering drugs being tested are being overlooked.

According to Professor McMurray, "Fortunately, some trials in progress are taking heart failure into account as a secondary outcome. But many others are neglecting to report this important complication as a key trial outcome. Until heart failure is systematically evaluated in , the cardiovascular safety of antidiabetes drugs will remain uncertain."

Explore further: Common diabetes drug fails to fulfill promise of improving cardiovascular risk in people without diabetes

More information: Study paper: www.thelancet.com/journals/landia/article/PIIS2213-8587(14)70031-2/abstract

Related Stories

Drug may improve outcomes after heart attack

March 12, 2013

The prescription drug eplerenone appears to reduce the risk of cardiovascular mortality and heart failure after a heart attack by more than one-third, according to research presented today at the American College of Cardiology's ...

Recommended for you

Resveratrol reverses heart damage in mice with Chagas disease

October 27, 2016

Resveratrol is the antioxidant found in red wine and famous as a food supplement capable of mimicking the effects of exercise and low calorie diets in the heart. Now Vilar-Pereira and colleagues show that treatment with resveratrol ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.